Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

NCT04830345 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2022-04-04

No results posted yet for this study

Summary

Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.

Conditions

  • Glabellar Frown Lines

Interventions

BIOLOGICAL

ATGC-100 100U

Clostridium botulinum toxin type A

BIOLOGICAL

Botox 100U

Clostridium botulinum toxin type A

Sponsors & Collaborators

  • EuBiologics Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2021-09-01
Completion
2021-10-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04830345 on ClinicalTrials.gov